Efficacy and Safety of Azithromycin for Uncomplicated Typhoid Fever: An Open Label Non-comparative Study
Efficacy and Safety of Azithromycin for Uncomplicated Typhoid Fever: An Open Label Non-comparative Study
复制标题
DOI：
10.1007/s13312-011-0093-y
复制
发表时间：
2011-07-01
影响因子：
2.3
通讯作者：
Parikh, A. O.
中科院分区：
文献类型：
--
作者：
Aggarwal, Anju;Ghosh, Apurba;Parikh, A. O.
本文对117名2-12岁儿童进行了一项开放性、非对照性研究，以评价阿奇霉素（20 mg/kg/d，连续6天）治疗单纯性伤寒的疗效和安全性。在根据伤寒临床定义入组的患者中，109例（93.1%）完成了研究。就诊时发热持续时间的平均SD为9.1（4.5）天。在102例（93.5%）受试者中观察到临床治愈，7例因临床恶化退出研究。平均缓解日为3.45 +/- 1.97。BACTEC血培养伤寒沙门氏菌阳性17/109例（15.5%），均达到细菌学治愈。未观察到严重不良事件。在治疗结束时，研究者和受试者对95%病例的总体健康状况评估良好。阿奇霉素被认为是安全和有效的管理简单的伤寒。
An open-labelled, non-comparative study was conducted in 117 children aged 2-12 years to evaluate the efficacy and safety of azithromycin 20mg/kg/day for 6 days) for the treatment of uncomplicated typhoid fever. Of the patients enrolled based on a clinical definition of typhoid fever, 109 (93.1%) completed the study. Mean SD) of duration of fever at presentation was 9.1(4.5) days. Clinical cure was seen in 102 (93.5%) subjects, while 7 were withdrawn from the study because of clinical deterioration. Mean day of response was 3.45 +/- 1.97. BACTEC blood culture was positive for Salmonella typhi in 17/109 (15.5%) and all achieved bacteriological cure. No serious adverse event was observed. Global well being assessed by the investigator and subjects was good in 95% cases which was done at the end of the treatment. Azithromycin was found to be safe and efficacious for the management of uncomplicated typhoid fever.